TY - JOUR
T1 - Redirected cellular cytotoxicity employing bispecific antibodies and other multifunctional binding proteins
AU - Weiner, Louis M.
AU - Alpaugh, R. Katherine
AU - Von Mehren, Margaret
PY - 1997
Y1 - 1997
N2 - Commencing with the discovery and characterization of bispecific antibodies, numerous investigations have shown that such antibodies are capable of redirecting cellular cytotoxicity. Clinical trials testing diverse strategies, including those targeting CD16-expressing effector cells, have been conducted or are in progress. This manuscript reviews our clinical trials efforts with bispecific antibodies and describes our experience employing multifunctional binding proteins containing tumor-targeting antibody Fab fragments linked to bacterial superantigens, such as staphylococcal enterotoxin A.
AB - Commencing with the discovery and characterization of bispecific antibodies, numerous investigations have shown that such antibodies are capable of redirecting cellular cytotoxicity. Clinical trials testing diverse strategies, including those targeting CD16-expressing effector cells, have been conducted or are in progress. This manuscript reviews our clinical trials efforts with bispecific antibodies and describes our experience employing multifunctional binding proteins containing tumor-targeting antibody Fab fragments linked to bacterial superantigens, such as staphylococcal enterotoxin A.
KW - Bispecific antibody
KW - Cytotoxicity
KW - HER2/neu CD16
KW - Staphylococcal enterotoxin A
UR - http://www.scopus.com/inward/record.url?scp=0030783183&partnerID=8YFLogxK
U2 - 10.1007/s002620050430
DO - 10.1007/s002620050430
M3 - Article
C2 - 9435871
AN - SCOPUS:0030783183
SN - 0340-7004
VL - 45
SP - 190
EP - 192
JO - Cancer Immunology Immunotherapy
JF - Cancer Immunology Immunotherapy
IS - 3-4
ER -
